Defactinib is a FAK inhibitor that has undergone encouraging clinical trials in association with the MEK inhibitor avutometinib for the treatment of low-grade ovarian serous cancer, as shown in Table 2. The gene discussed is MAP2K7; the disease is ovarian serous adenocarcinoma.